Evidence map›Paper›PMID 27576317›Full record

ReviewNephron2016

Endothelial Dysfunction in Renal Interstitial Fibrosis.

Heather M Perry, Mark D Okusa

Open access · bronzeAbstract readReview
In one paragraph

Review in Nephron, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Arginase-2 mediates renal ischemia-reperfusion injury.American journal of physiology. Renal physiology · 2017
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Heather M PerryDivision of Nephrology, Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia Health System, Charlottesville, Va., USA.
Mark D Okusa
University of Virginia Health System · US

Funding

Sphingolipids in Acute Kidney Injury and Disease ProgressionR01DK085259 · NIDDK · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2010 to 2023
$5.0M
Leukocyte Trafficking in Acute Renal FailureR01DK062324 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI OKUSA, MARK DOUGLAS · 2003 to 2016
$4.4M
Kidney Disease and InflammationT32DK072922 · NIDDK · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2006 to 2020
$2.6M
Ultrasound for Non-Invasive Prevention of Acute Kidney InjuryR01DK105133 · NIDDK · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2015 to 2019
$2.4M
Endothelial sphingosine-1-phosphate receptor 1 regulates renal recovery after acute kidney injuryF32DK108563 · NIDDK · UNIVERSITY OF VIRGINIA · PI PERRY, HEATHER M. · 2015 to 2017
$115k
NIDDK NIH HHS F32 DK108563NIDDK NIH HHS R01 DK062324NIDDK NIH HHS R01 DK085259NIDDK NIH HHS R01 DK105133NIDDK NIH HHS T32 DK072922
6 · The paper itself

Abstract

Kidney disease affects millions of people worldwide and it is now widely accepted that many pathological processes may persist after acute kidney injury that can cause the progression to CKD. Tubulointerstitial fibrosis manifests soon after injury and while many cellular and molecular components of kidney fibrosis have been discovered, largely in animal models, new therapeutic strategies are still desperately needed. The renal endothelium has emerged as important in progression of fibrosis through regulation of hypoxia, inflammation and cellular crosstalk. This review aims to highlight our current understanding of the role of the endothelium in interstitial fibrosis and to identify potential therapeutic targets. © 2016 S. Karger AG, Basel.

Indexed as

EndotheliumFibrosisHumansKidney Diseases

Identifiers

PMID27576317
PMCPMC5089917
OpenAlexW2511932431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.